I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong
suspicion of neuroblastoma or pheochromocytoma.
Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of
I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after
administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid
uptake of free I-123-iodide
Observational Model: Case-Only
Michael J Gelfand, M.D.
Children's Hospital Medical Center, Cincinnati
United States: Food and Drug Administration